MRK

Business Context and Reporting Period

This Form 10-Q covers Schering-Plough Corporation for the quarterly period ended September 30, 2003. The company operates in three segments: Human Pharmaceuticals, Consumer Health Care, and Animal Health Care. The reporting period is characterized by significant headwinds, including the loss of market exclusivity for key products, intense generic competition, and substantial legal and regulatory investigations.

Key Financial Metrics

Note: Debt consists primarily of short-term commercial paper borrowings. Cash and short-term investments totaled $4,306 million as of September 30, 2003.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 16% in Q3 and 17% for the nine-month period. This was driven by a 22% volume decline in Q3, primarily due to the rapid drop in prescription CLARITIN sales following its conversion to OTC status and the expiration of market exclusivity.
• Profitability Collapse: The company reported a net loss of $265 million in Q3 compared to a profit of $429 million in the prior year. This reversal was largely caused by a $350 million non-tax deductible provision to increase litigation reserves related to federal investigations into marketing and sales practices.
• Segment Performance:
  • Human Pharmaceuticals: Sales dropped 24% (Q3) due to declines in the INTRON franchise (hepatitis C) and CLARITIN. However, ZETIA (cholesterol) sales grew significantly.
  • Consumer Health Care: Sales surged 109% (Q3) driven by the launch of OTC CLARITIN, though private-label competition has emerged.
• Cash Flow: Operating cash flow for the nine months ended September 30, 2003, fell to $375 million from $1,484 million in the prior year, reflecting lower earnings and working capital changes.

Guidance, Outlook, and Risks

• Outlook: Management expects earnings per share (EPS) for the second half of 2003 and all of 2004 to be lower than the previous year. Q4 2003 EPS is expected to be below Q3 levels (excluding the litigation charge) due to continued contraction in the hepatitis franchise and trade inventory reductions.
• Cost Cutting: The company announced accelerated cost-cutting, including a Voluntary Early Retirement Program expected to incur a pre-tax charge of approximately $150 million in Q4 2003.
• Dividend Reduction: The quarterly dividend was reduced from $0.17 to $0.055 per share to preserve cash.
• Legal and Regulatory Risks:
  • Investigations: The company is a target of federal criminal investigations (Boston Target Letter) regarding off-label promotion, anti-kickback statutes, and Medicaid rebate calculations. A $350 million reserve was added in Q3.
  • Consent Decree: Ongoing compliance with an FDA consent decree regarding manufacturing practices carries potential penalties of up to $175 million if deadlines are missed.
  • Patent Litigation: Adverse court rulings regarding the desloratadine patent (CLARITIN) have been sustained, exposing the company to generic competition.
• Credit Ratings: Major rating agencies (S&P, Moody's, Fitch) downgraded the company's credit ratings in late 2003 due to declining earnings and cash flow, maintaining negative outlooks.

Investor Verification Checklist

• Litigation Reserve Adequacy: Verify if the $350 million provision is sufficient to cover potential settlements from the U.S. Attorney's Offices in Massachusetts and Pennsylvania.
• CLARITIN Transition: Monitor the erosion of prescription CLARITIN sales versus the growth and competitive pressure on OTC CLARITIN and CLARINEX.
• Liquidity Position: Assess the company's ability to refinance its $2.5 billion in short-term commercial paper given the credit rating downgrades and reduced operating cash flow.
• Manufacturing Compliance: Track progress on the FDA consent decree revalidation programs to avoid additional penalties or production halts.
• Dividend Sustainability: Confirm the long-term viability of the reduced dividend given the projected cash flow deficits in 2003 and 2004.